Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2020; 11(10): 400-415
Published online Oct 15, 2020. doi: 10.4239/wjd.v11.i10.400
Published online Oct 15, 2020. doi: 10.4239/wjd.v11.i10.400
Type 1 diabetes mellitus and its oral tolerance therapy
Rui-Feng Mao, Jiangsu Collaborative Innovation Center of Regional Modern Agriculture and Environmental Protection, School of Life Science, Huaiyin Normal University, Huai'an 223300, Jiangsu Province, China
Ying-Ying Chen, Ji Zhang, School of Life Sciences, Huaiyin Normal University, Huai'an 223300, Jiangsu Province, China
Xin Chang, Department of Ultrasound Medicine, Nanjing Lishui People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, Jiangsu Province, China
Ye-Fu Wang, College of Life Sciences, Wuhan University, Wuhan 430072, Hubei Province, China
Author contributions: Mao RF conceived and designed the study; Chen YY wrote the manuscript; Zhang J searched and classified the literature; Chang X and Wang YF revised the manuscript; all authors approved the final version of this manuscript.
Supported by National Natural Science Foundation of China , No. 81803418 ; Natural Science Foundation of the Jiangsu Higher Education Institutions , No. 18KJD350001 ; and Project for Youth Scholar of Jiangsu Collaborative Innovation Center of Regional Modern Agriculture and Environmental Projection , No. HSXT2-314 .
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui-Feng Mao, PhD, Research Scientist, Teacher, Jiangsu Collaborative Innovation Center of Regional Modern Agriculture and Environmental Protection, School of Life Sciences, Huaiyin Normal University, No. 111 Changjiang West Road, Huai'an 223300, Jiangsu Province, China. mmrf2008@163.com
Received: May 23, 2020
Peer-review started: May 23, 2020
First decision: July 25, 2020
Revised: July 27, 2020
Accepted: August 31, 2020
Article in press: August 31, 2020
Published online: October 15, 2020
Processing time: 144 Days and 2.5 Hours
Peer-review started: May 23, 2020
First decision: July 25, 2020
Revised: July 27, 2020
Accepted: August 31, 2020
Article in press: August 31, 2020
Published online: October 15, 2020
Processing time: 144 Days and 2.5 Hours
Core Tip
Core Tip: As an antigen-specific immunotherapy, oral tolerance therapy has shown promise as a new strategy for the prevention and treatment of autoimmune diseases, including type 1 diabetes mellitus. Oral tolerance therapy in type 1 diabetes mellitus has been studied widely for a long time. In order to give a better understanding of these studies performed in animal models as well as in clinical trials, we review the related reports carefully and divide these studies into various categories based on their strategies. This careful review may be useful to guide the future studies.